BioAge Labs, Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
BIOA$5.78+1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
Unaudited Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share information)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common stock · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance, December 31, 2025 | 37,386,908 | — | $605,189 | $278 | $(333,416) | $272,051 |
| Underwritten stock offering, net of underwriting discounts and commissions, and offering expenses | 6,782,050 | — | 123,557 | — | — | 123,557 |
| Stock option exercises | 217,827 | — | 1,715 | — | — | 1,715 |
| Stock-based compensation expense | — | — | 4,256 | — | — | 4,256 |
| Unrealized loss on marketable securities | — | — | — | (178) | — | (178) |
| Foreign currency translation adjustment | — | — | — | (27) | — | (27) |
| Net loss | — | — | — | — | (22,253) | (22,253) |
| Balance, March 31, 2026 | 44,386,785 | $— | $734,717 | $73 | $(355,669) | $379,121 |
| Issuance of common shares under at-the-market sales agreement, net of placement agent fee and offering costs | 1,000,000 | — | 15,637 | — | — | 15,637 |
| Stock option exercises | 390,117 | — | 2,534 | — | — | 2,534 |
| Stock-based compensation expense | — | — | 4,269 | — | — | 4,269 |
| Unrealized loss on marketable securities | — | — | — | (547) | — | (547) |
| Foreign currency translation adjustment | — | — | — | (4) | — | (4) |
| Net loss | — | — | — | — | (26,097) | (26,097) |
| Balance, June 30, 2026 | 45,776,902 | $— | $757,157 | $(478) | $(381,766) | $374,913 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common stock · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Income | Deficit | Equity | |
| Balance, December 31, 2024 | 35,850,037 | $— | $575,693 | $245 | $(252,811) | $323,127 |
| Stock-based compensation expense | — | — | 2,949 | — | — | 2,949 |
| Unrealized gain on marketable securities | — | — | — | 29 | — | 29 |
| Foreign currency translation adjustment | — | — | — | (10) | — | (10) |
| Net loss | — | — | — | — | (12,928) | (12,928) |
| Balance, March 31, 2025 | 35,850,037 | $— | $578,642 | $264 | $(265,739) | $313,167 |
| Stock-based compensation expense | — | — | 3,229 | — | — | 3,229 |
| Foreign currency translation adjustment | — | — | — | (52) | — | (52) |
| Net loss | — | — | — | — | (21,563) | (21,563) |
| Balance, June 30, 2025 | 35,850,037 | — | 581,871 | 212 | (287,302) | 294,781 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.